Industry Briefs: Mar. 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Galapagos has received EUR 3.5 million ($4.59 million) in milestone payments in its osteoarthritis alliance with Servier. Read More

JHP Pharmaceuticals has added a second product to its previously announced multiyear contract manufacturing agreement with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent. Read More

Lonza and Eclipse Therapeutics have formed a development and manufacturing agreement. Read More

Mylan continues to pursue damages and and its injunction against Sunovion’s Brovana in an ongoing litigation. Mylan believes a federal district court erred in its partial summary judgment decision. Read More

Pfenex and DNA2.0 have formed a collaboration on protein expression technology. Read More

People News

Albany Molecular Research (AMRI) has named Tom McGrath as director of quality for aseptic services, and Chris Phillips has been appointed to the role of senior director of operations, at AMRI’s Burlington, Massachusetts site. Read More

Alkermes has appointed Mark Stejbach as chief commercial officer. Read More

AstraZeneca has announced the retirement of Louis Schweitzer from the board as chairman and as a director, effective Sept. 1, 2012. Read More

Novartis has named Brian McNamara division head of Novartis OTC. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here